Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06736704 · ClinicalTrials.gov registry record · Phase 1

SNV4818 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Pikavation Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
320
Enrollment target
12
Study locations

NCT06736704 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Pikavation Therapeutics. The registered enrollment target is 320 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (63% higher). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06736704, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Pikavation Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
320 participants
Enrollment target
12
Study locations

Study Summary

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG SNV4818
  • DRUG Fulvestrant
  • DRUG Palbociclib

Study Locations (12)

New South Wales

  • Chris O'Brien Lifehouse - Camperdown
  • Scientia Clinical Research - Randwick

Victoria

  • Monash Health - Clayton
  • Peter MacCallum Cancer Centre - Melbourne

Ontario

  • The Ottawa Hospital Cancer Centre - Ottawa
  • University Health Network, Princess Margaret Cancer Centre - Toronto

California

  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate - Los Angeles

Massachusetts

  • Massachusetts General Hospital - Boston

Pennsylvania

  • Thomas Jefferson University-Sidney Kimmel Cancer Center - Philadelphia

Tennessee

  • Sarah Cannon Research Institute - Nashville

Texas

  • The University of Texas M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2025-02-20
Est. Completion 2027-06
Phase Phase 1

Sponsor

Pikavation Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06736704

The ClinicalTrials.gov registry entry for NCT06736704 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (63% higher). The listed sponsor is Pikavation Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which SNV4818 is the first listed.

NCT06736704 reports 12 study locations spanning 9 distinct geographic areas - top geographies include New South Wales, Victoria, Ontario.

Frequently Asked Questions

What is clinical trial NCT06736704 about?

NCT06736704 is a clinical study titled "SNV4818 in Participants With Advanced Solid Tumors". This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

What is the current status of trial NCT06736704?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2025-02-20. Estimated completion is 2027-06.

What conditions does trial NCT06736704 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06736704?

The interventions under investigation include: SNV4818 (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG).

Who is sponsoring clinical trial NCT06736704?

This trial is sponsored by Pikavation Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06736704 being conducted?

This trial has 12 study locations across California, Massachusetts, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.